In the latter case, it’s harder to argue that the model has been a success -trading around cash, despite the sale of Karuna (to BMS) for $14bn. However, the company has raised $200m in an attempt to repeat its success in Neuroscience.
My personal take is that whichever model you choose, as an emerging biotech, it remains extremely rare to successfully develop & commercialise a NAS. It seems much of the effort is focussed on attempts to de-risk the biology but there has to be a commensurate attempt to disrupt the clinical trial business as the inexorable rise in costs is killing biotech.
It’s interesting you published this article on the same day that Pure tech (another hub and spoke company) was featured in an in-depth piece in Biopharma Dive. https://www.biopharmadive.com/news/puretech-biotech-incubator-startup-chowrira-elenko/730058/
In the latter case, it’s harder to argue that the model has been a success -trading around cash, despite the sale of Karuna (to BMS) for $14bn. However, the company has raised $200m in an attempt to repeat its success in Neuroscience.
My personal take is that whichever model you choose, as an emerging biotech, it remains extremely rare to successfully develop & commercialise a NAS. It seems much of the effort is focussed on attempts to de-risk the biology but there has to be a commensurate attempt to disrupt the clinical trial business as the inexorable rise in costs is killing biotech.
Wow, super interesting article. Thanks!
Incredibly interesting.
Fantastic article Elliot! I learned a ton!